- Home
- MWA vs MIRM Comparison
MWA vs MIRM Comparison
Compare MWA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MWA | MIRM |
|---|---|---|
| Founded | 1857 | 2018 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.7B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MWA | MIRM |
|---|---|---|
| Price | $28.49 | $95.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $30.50 | ★ $115.33 |
| AVG Volume (30 Days) | ★ 833.5K | 788.7K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | 64.86 | ★ 74.59 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $1,429,700,000.00 | $19,138,000.00 |
| Revenue This Year | $4.85 | $26.22 |
| Revenue Next Year | $4.20 | $22.04 |
| P/E Ratio | $108.00 | ★ N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $22.74 | $38.22 |
| 52 Week High | $31.00 | $109.28 |
Technical Indicators
Market Signals| Indicator | MWA | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 52.36 |
| Support Level | $26.66 | $85.35 |
| Resistance Level | $28.54 | $98.03 |
| Average True Range (ATR) | 0.81 | 3.62 |
| MACD | 0.13 | 0.44 |
| Stochastic Oscillator | 42.30 | 67.06 |
Price Performance
Historical ComparisonAbout MWA MUELLER WATER PRODUCTS
Mueller Water Products Inc is a U.S.-based company that manufactures and sells products and services used in the transmission, distribution, and measurement of water. The company operates in two segments: Water Flow Solutions and Water Management Solutions. The Water Flow Solutions segment, which derives maximum revenue for the company, includes products like iron gate valves, specialty valves, and service brass products. Water Management Solutions' portfolio includes fire hydrants, repair and installation, natural gas, metering, leak detection, and pressure management and control products and solutions. Geographically, the company derives a majority of its revenue from the United States and the rest from Canada and other international locations.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.